SAPHO Syndrome Complicated by Lesions of the Central Nervous System Successfully Treated with Brodalumab

Synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO) syndrome is a rare disease with an unknown entity that affects the skin and the peripheral and/or axial joints. Here, we report on a patient with SAPHO syndrome complicated by lesions of the central nervous system who was successfully treated w...

Full description

Saved in:
Bibliographic Details
Main Authors: Masahide Funabiki, Masayuki Tahara, Seiko Kondo, Naho Ayuzawa, Hidetoshi Yanagida
Format: Article
Language:English
Published: Wiley 2023-01-01
Series:Case Reports in Rheumatology
Online Access:http://dx.doi.org/10.1155/2023/6005531
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850218273110491136
author Masahide Funabiki
Masayuki Tahara
Seiko Kondo
Naho Ayuzawa
Hidetoshi Yanagida
author_facet Masahide Funabiki
Masayuki Tahara
Seiko Kondo
Naho Ayuzawa
Hidetoshi Yanagida
author_sort Masahide Funabiki
collection DOAJ
description Synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO) syndrome is a rare disease with an unknown entity that affects the skin and the peripheral and/or axial joints. Here, we report on a patient with SAPHO syndrome complicated by lesions of the central nervous system who was successfully treated with brodalumab, an IL-17 receptor blocker. He had been suffering from arthralgia in the wrists and knees as well as axial symptoms such as back pain and assimilation of cervical vertebrae. He had been treated with corticosteroid, salazosulfapyridine, methotrexate, and bisphosphonate; however, his peripheral and axial articular manifestation were intractable. Recently, biologics predominantly targeting TNF-α is employed for difficult-to-treat SAPHO cases; however, he had been complicated with the lesions of the central nervous system resembling multiple sclerosis (MS), an inflammatory demyelinating disorder in the central nervous system, for which application of TNF-α inhibitor is contraindicated. Alternatively, brodalumab was administered , which promptly ameliorated the articular manifestations without aggravating the lesions of the central nervous system. We propose that this type of IL-17 blockade could be an alternative therapy for DMARDs-resistant SAPHO syndrome.
format Article
id doaj-art-3d66e4780d7042369fc46022e06306a2
institution OA Journals
issn 2090-6897
language English
publishDate 2023-01-01
publisher Wiley
record_format Article
series Case Reports in Rheumatology
spelling doaj-art-3d66e4780d7042369fc46022e06306a22025-08-20T02:07:48ZengWileyCase Reports in Rheumatology2090-68972023-01-01202310.1155/2023/6005531SAPHO Syndrome Complicated by Lesions of the Central Nervous System Successfully Treated with BrodalumabMasahide Funabiki0Masayuki Tahara1Seiko Kondo2Naho Ayuzawa3Hidetoshi Yanagida4Department of RheumatologyDepartment of NeurologyDepartment of RheumatologyDepartment of RheumatologyDepartment of RheumatologySynovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO) syndrome is a rare disease with an unknown entity that affects the skin and the peripheral and/or axial joints. Here, we report on a patient with SAPHO syndrome complicated by lesions of the central nervous system who was successfully treated with brodalumab, an IL-17 receptor blocker. He had been suffering from arthralgia in the wrists and knees as well as axial symptoms such as back pain and assimilation of cervical vertebrae. He had been treated with corticosteroid, salazosulfapyridine, methotrexate, and bisphosphonate; however, his peripheral and axial articular manifestation were intractable. Recently, biologics predominantly targeting TNF-α is employed for difficult-to-treat SAPHO cases; however, he had been complicated with the lesions of the central nervous system resembling multiple sclerosis (MS), an inflammatory demyelinating disorder in the central nervous system, for which application of TNF-α inhibitor is contraindicated. Alternatively, brodalumab was administered , which promptly ameliorated the articular manifestations without aggravating the lesions of the central nervous system. We propose that this type of IL-17 blockade could be an alternative therapy for DMARDs-resistant SAPHO syndrome.http://dx.doi.org/10.1155/2023/6005531
spellingShingle Masahide Funabiki
Masayuki Tahara
Seiko Kondo
Naho Ayuzawa
Hidetoshi Yanagida
SAPHO Syndrome Complicated by Lesions of the Central Nervous System Successfully Treated with Brodalumab
Case Reports in Rheumatology
title SAPHO Syndrome Complicated by Lesions of the Central Nervous System Successfully Treated with Brodalumab
title_full SAPHO Syndrome Complicated by Lesions of the Central Nervous System Successfully Treated with Brodalumab
title_fullStr SAPHO Syndrome Complicated by Lesions of the Central Nervous System Successfully Treated with Brodalumab
title_full_unstemmed SAPHO Syndrome Complicated by Lesions of the Central Nervous System Successfully Treated with Brodalumab
title_short SAPHO Syndrome Complicated by Lesions of the Central Nervous System Successfully Treated with Brodalumab
title_sort sapho syndrome complicated by lesions of the central nervous system successfully treated with brodalumab
url http://dx.doi.org/10.1155/2023/6005531
work_keys_str_mv AT masahidefunabiki saphosyndromecomplicatedbylesionsofthecentralnervoussystemsuccessfullytreatedwithbrodalumab
AT masayukitahara saphosyndromecomplicatedbylesionsofthecentralnervoussystemsuccessfullytreatedwithbrodalumab
AT seikokondo saphosyndromecomplicatedbylesionsofthecentralnervoussystemsuccessfullytreatedwithbrodalumab
AT nahoayuzawa saphosyndromecomplicatedbylesionsofthecentralnervoussystemsuccessfullytreatedwithbrodalumab
AT hidetoshiyanagida saphosyndromecomplicatedbylesionsofthecentralnervoussystemsuccessfullytreatedwithbrodalumab